0HNC.LSE BioMarin Pharmaceutical Inc.

Healthcare Biotechnology London Exchange
- USD
Market cap
-
P/E
270.5x
P/B
-
ROE
4.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 0HNC.LSE undervalued?

Graham number

The Graham number of BioMarin Pharmaceutical Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BioMarin Pharmaceutical Inc. fundamental analysis

No fundamental analysis for BioMarin Pharmaceutical Inc. yet.

BioMarin Pharmaceutical Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c…

Full company profile